GlassScriptPhysician profile
Evan Keith Brady
NPI 1265827380
$4,496.79
in general payments reported to CMS, 2019-2025
36 companies · $924 in 2025
The $924 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $811 · 2022: $801 · 2023: $1,180 · 2024: $782 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,870 · Education: $14.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,869.94 |
| Education | $14.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,184.49 | 2021-2025 | Rinvoq, Skyrizi, Mavyret |
| Gilead Sciences, INC. | $401.41 | 2021-2025 | |
| Genzyme Corporation | $279.16 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $261.69 | 2021-2024 | Entyvio, Gattex |
| Pfizer INC. | $216.97 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $207.05 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $194.05 | 2022-2025 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $178.02 | 2021-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.64 | 2022-2025 | Xifaxan |
| Amgen INC. | $135.09 | 2021-2023 | Amjevita, Avsola |
| Merck Sharp & Dohme LLC | $113.65 | 2021-2024 | Dificid |
| Ardelyx, INC. | $112.63 | 2023-2025 | Ibsrela |
| Celgene Corporation | $110.85 | 2021-2024 | Zeposia |
| Medtronic, INC. | $97.27 | 2021-2025 | Gi Genius, Endoflip |
| Phathom Pharmaceuticals, INC. | $80.72 | 2024-2025 | Voquezna |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $78.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $73.73 | 2023-2025 | Watchman Flx, Captivator II |
| Ironwood Pharmaceuticals, INC | $70.14 | 2021-2023 | Linzess |
| Pentax of America, INC. | $67.06 | 2021 | |
| Celltrion USA INC. | $53.60 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $49.56 | 2021-2023 | Sutab |
| Fresenius Kabi USA, LLC | $48.64 | 2023-2024 | Idacio |
| Daiichi Sankyo INC. | $44.52 | 2022-2023 | Injectafer |
| Organon LLC | $36.44 | 2023-2024 | Hadlima, Renflexis |
| Olympus America INC. | $33.38 | 2021-2023 | Evis Exera Lll Colonovideoscope |
| E.R. Squibb & Sons, L.L.C. | $33.20 | 2022 | |
| Janssen Scientific Affairs, LLC | $32.03 | 2023 | Stelara |
| Mauna Kea Technologies, INC. | $27.66 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $26.76 | 2025 | |
| Nestle Healthcare Nutrition INC. | $17.65 | 2021 | |
| Vivus LLC | $16.43 | 2021 | |
| Lilly USA, LLC | $15.87 | 2025 | Omvoh |
| Merit Medical Systems INC | $14.91 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $14.01 | 2025 | Iqirvo |
| Qol Medical, LLC | $12.76 | 2021 | |
| Intra-Sana Laboratories | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.